OBJECTIVE To monitor the Enterobacter cloacae resistance in our hospital patients.METHODS Disk susceptibility tests were performed for detection of E.cloacae resistance to 10 antibiotics,Detection of(extended)-spectrum ?-lactamases and AmpC ?-lactamase was conducted by three-dimensional extract test.RESULTS Seventy four strains of E.cloacae were isolated from our hospital patients,its had high resistant rate to 9 antibiotics(from(40.5%) to 91.8%),Among 74 strains of E.cloacae,10 isolates(13.5%) were considered as AmpC enzyme producing,31 strains(41.89%) were ESBLs-producing,6 strains(8.1%) were producing both of them.Total detection of AmpC(?-lactamase),or the production of ESBLs,or both of them were 47 strains(63.5%).Only imipenem was effective for all E.cloacae.CONCLUSIONS For the serious infection induced by E.cloacae producing AmpC ?-lactamase or(ESBLs),imipenem is first choice of treatment.

Objective: To evaluate the role of endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) in lymph node staging and resectability assessment of patients with non-small cell lung cancer (NSCLC). Methods: The clinical data of 154 patients with NSCLC who underwent EBUS-TBNA from March 2015 to December 2018 were collected. All accessible mediastinal and hilar lymph nodes were systematically explored and punctured using EBUS-TBNA. EBUS-TBNA and CT were used for preoperative staging and resectability evaluation. Results: The sensitivity, specificity and accuracy of EBUS-TBNA were 94.2%, 100.0% and 96.0%, respectively, while those of CT were 89.9%, 31.8% and 72.0%, respectively. The differences were statistically significant (P<0.05). The sensitivity, specificity and accuracy of EBUS-TBNA in lymph nodes with short diameter less than 15 mm were 92.4%, 100.0% and 96.0%, respectively, while those of CT were 80.7%, 34.8% and 60.1%, respectively, with statistical differences (P<0.05). The staging of 62 patients was changed, 27 cases were up-regulated and 35 cases were down-regulated. Among them, 32 cases had been changed to resectable. The evaluating resectability of EBUS-TBNA showed excellent consistency with that of pathological results (Kappa=0.95). The sensitivity and specificity were 100.0% and 97.2%, respectively. Conclusion EBUS-TBNA can systemically evaluate the metastatic status of NSCLC patients and improve the accuracy of preoperative lymph node staging and resectability assessment.

Objective To evaluate the role of endobronchial ultrasound guided transbronchial needle aspiration (EBUS?TBNA) in lymph node staging and resectability assessment of patients with non?small cell lung cancer (NSCLC). Methods The clinical data of 154 patients with NSCLC who underwent EBUS?TBNA from March 2015 to December 2018 were collected. All accessible mediastinal and hilar lymph nodes were systematically explored and punctured using EBUS?TBNA. EBUS?TBNA and CT were used for preoperative staging and resectability evaluation.Results The sensitivity, specificity and accuracy of EBUS?TBNA were 94.2%, 100.0% and 96.0%, respectively, while those of CT were 89.9%, 31.8% and 72.0%, respectively.The differences were statistically significant (P＜0.05).The sensitivity, specificity and accuracy of EBUS?TBNA in lymph nodes with short diameter less than 15 mm were 92.4%, 100.0% and 96.0%, respectively, while those of CT were 80.7%, 34.8% and 60.1%, respectively, with statistical differences (P＜0.05). The staging of 62 patients was changed, 27 cases were up?regulated and 35 cases were down?regulated. Among them, 32 cases had been changed to resectable. The evaluating resectability of EBUS?TBNA showed excellent consistency with that of pathological results ( Kappa＝0.95). The sensitivity and specificity were 100.0% and 97.2%, respectively. Conclusion EBUS?TBNA can systemically evaluate the metastatic status of NSCLC patients and improve the accuracy of preoperative lymph node staging and resectability assessment.

Objective To evaluate the role of endobronchial ultrasound guided transbronchial needle aspiration (EBUS?TBNA) in lymph node staging and resectability assessment of patients with non?small cell lung cancer (NSCLC). Methods The clinical data of 154 patients with NSCLC who underwent EBUS?TBNA from March 2015 to December 2018 were collected. All accessible mediastinal and hilar lymph nodes were systematically explored and punctured using EBUS?TBNA. EBUS?TBNA and CT were used for preoperative staging and resectability evaluation.Results The sensitivity, specificity and accuracy of EBUS?TBNA were 94.2%, 100.0% and 96.0%, respectively, while those of CT were 89.9%, 31.8% and 72.0%, respectively.The differences were statistically significant (P＜0.05).The sensitivity, specificity and accuracy of EBUS?TBNA in lymph nodes with short diameter less than 15 mm were 92.4%, 100.0% and 96.0%, respectively, while those of CT were 80.7%, 34.8% and 60.1%, respectively, with statistical differences (P＜0.05). The staging of 62 patients was changed, 27 cases were up?regulated and 35 cases were down?regulated. Among them, 32 cases had been changed to resectable. The evaluating resectability of EBUS?TBNA showed excellent consistency with that of pathological results ( Kappa＝0.95). The sensitivity and specificity were 100.0% and 97.2%, respectively. Conclusion EBUS?TBNA can systemically evaluate the metastatic status of NSCLC patients and improve the accuracy of preoperative lymph node staging and resectability assessment.